Coldplay may have answered EMI's rumored hopes
Elizabeth Taylor and Kathy Ireland walk away from jewelry company
More controls not the answer for China
KKR still has IPO envy?
Liquidnet looks for IPO liquidity
Energy Recovery: a cleantech deal hits the IPO market
Booze a defensive play in a bear market
Dollar rises vs euro after ECB's Trichet signals one rate hike may be enough
Who will make the next generation of thinner TVs: Samsung, Sony, Panasonic or Toshiba?_thumbnail.gif){kind=logo}
Analyst downgrades: NVDA, AFLYY and UNH
Sprint Nextel finally in the midst of a turnaround?
U.S. weekly jobless claims pass 400k, signaling further economic slowing
Blockbuster could come back for Circuit City?
Yahoo! (YHOO) looks for another partner
Before the bell: AMR, GOOG, AAPL
Lehman issuing stock to employees smells of desperation
Merck & Co. (NYSE: MRK) said it will eliminate 1,200 U.S. sales jobs, about 15% of the drugmaker's sales force. This comes after last week the FDA rejected its experimental cholesterol pill Cordaptive.The third-largest U.S. drugmaker has cut 8,100 jobs globally since the beginning of its restructuring plan, Plan to Win, in late 2005. But as Cordaptive, which was supposed to offset some of the losses Merck is expecting from generics coming into the market, fell through, the cost cutting side of the plan took on an added urgency.
Cordaptive and generics aren't Merck's only problem. The FDA also recently suggested its other cholesterol pills, Zetia and Vytorin, aren't any better than an older, cheaper treatment. Merck said it expects to lose as much as 61% of sales for these drugs.
So none of this comes as no surprise really; not in light of Merck's problems, and not in light of the industry's. Other drugmakers, including Pfizer Inc. (NYSE: PFE), Bristol-Myers Squibb Co. (NYSE: BMY), Wyeth (NYSE: WYE) and Johnson & Johnson (NYSE: JNJ) have announced job cuts as they face more competition from generic substitutions. Merck is also planning some plant closures.
Merck's shares lost nearly 33% of their value year-to-date, as it was partly down with the overall market and partly due to the string of bad news that seemed to have hit most hard recently. It is trading not far from its 52-week low.
While Merck is saying it will still fight the FDA decision on Cordaptive and try to convince doctors about Vytorin, the actions it is taking seem reactive, not proactive. Without much to offer in its arsenal of upcoming possibilities, Merck, at least for now, seems to have lost the potential for meaningful growth.
Reader Comments (Page 1 of 1)
1. That's a shame. I think cutting jobs should be the last resort, but that's what happens when u throw a punch. You almost always get hit back.
Business Credit Cards
http://satxxkenn.sitemighty.com/category/business-cards
Posted at 2:01PM on May 16th 2008 by Kenneth